Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) a Buy, Sell, or Hold?
NASDAQ : COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$50.22 USD
$0.93 (1.89%)
- Volume
- 155.01K
- Average Volume
- 350.38K
- Market Capitalization
- $100.88M
- P/E Ratio
- -21.55
- Dividend Yield
- 0.00%
- Price Target
- $50.00
- Year High
- $52.15
- Year Low
- $23.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.03
Company Overview
NASDAQ
Benny Sorensen
Biotechnology
Healthcare
COAG
59
US
USD
Liquidity Metrics
-0.01
18.03
18.03
8.24
0.00
Sales & Valuation
-$
0.00
-7.80
-1.64
-2.24
Profitability
-$2.33
-$63.91M
0.00%
0.00%
36.18%
-32.81%
P/E Metrics
-21.55
-0.22
-0.22
Analyst Price Target & Rating
$50.00
$55.00
$36.00
2/5
3 Analysts
0.44%
Poll Results
No votes yet today — be the first to share your view!
About Hemab Therapeutics Holdings, Inc. Common Stock (NASDAQ:COAG) Stock
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company ... actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5% – Should You Buy?
2026-07-19 04:02:08
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report)'s share price traded up 5.5% on Friday. The stock traded as high as $47.00 and last traded at $47.00. 17,722 shares traded hands during trading, a decline of 93% from the average daily volume of 271,911 shares. The stock had previously closed at $44.53. Wall
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
2026-07-15 03:52:28
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations into 2029, supporting multiple clinical catalysts across sutacimig, HMB-002, and preclinical HMB-003. Lead asset sutacimig shows strong Phase 2 efficacy and FDA-aligned Phase 3 dosing, while HMB-002 and HMB-003 broaden addressable markets.
2026-07-14 07:45:00
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026
Hemab Advances Bleeding Disorder Pipeline
2026-07-13 13:47:15
Hemab Therapeutics Inc. (NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003, a new program targeting heavy menstrual bleeding, at the International Society on Thrombosis and Hemostasis (ISTH) 2026 Congress.
2026-07-12 06:28:00
HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing
2026-06-26 09:00:00
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
2026-06-08 23:05:15
Hemab Therapeutics NASDAQ: COAG Chief Executive Officer Benny Sorensen outlined the company's development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-27 08:00:00
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.
Frequently Asked Questions
-
What is the current Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock price?
-
Hemab Therapeutics Holdings, Inc. Common Stock(NASDAQ:COAG) stock price is $50.22 in the last trading session. During the trading session, COAG stock reached the peak price of $52.145 while $23 was the lowest point it dropped to. The percentage change in COAG stock occurred in the recent session was 1.89% while the dollar amount for the price change in COAG stock was $0.93.
-
COAG's industry and sector of operation?
-
The NASDAQ listed COAG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of COAG?
-
Catherine Madigan | Chief Medical Officer
Mads Nikolaj Behrndt-Eriksen | CFO & GM
Cecile Bonvoisin | Senior Vice President of CMC & Manufacturing
Benny Sorensen | President, CEO & Director
Ananthram Sreenivasa Murthy | Chief Operating Officer -
How many employees does COAG have?
-
Number of COAG employees currently stands at 59. COAG operates from 101 Main Street, Cambridge, MA 02142, US.
-
Link for COAG official website?
-
Official Website of COAG is: https://www.hemab.com
-
How do I contact COAG?
-
COAG could be contacted at phone #(617) 553-3952 and can also be accessed through its website. COAG operates from 101 Main Street, Cambridge, MA 02142, US.
-
How many shares of COAG are traded daily?
-
The average number of COAG shares traded daily for last 3 months was 350.38K.
-
What is the market cap of COAG currently?
-
The market value of COAG currently stands at $100.88M with its latest stock price at $50.22